- Home
- FHN vs QGEN Comparison
FHN vs QGEN Comparison
Compare FHN & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHN
- QGEN
- Stock Information
- Founded
- FHN 1864
- QGEN 1986
- Country
- FHN United States
- QGEN Netherlands
- Employees
- FHN N/A
- QGEN N/A
- Industry
- FHN Major Banks
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FHN Finance
- QGEN Health Care
- Exchange
- FHN Nasdaq
- QGEN Nasdaq
- Market Cap
- FHN 11.0B
- QGEN 10.7B
- IPO Year
- FHN N/A
- QGEN 1996
- Fundamental
- Price
- FHN $21.35
- QGEN $43.36
- Analyst Decision
- FHN Buy
- QGEN Buy
- Analyst Count
- FHN 20
- QGEN 7
- Target Price
- FHN $24.10
- QGEN $50.68
- AVG Volume (30 Days)
- FHN 16.2M
- QGEN 1.2M
- Earning Date
- FHN 10-15-2025
- QGEN 11-04-2025
- Dividend Yield
- FHN 2.81%
- QGEN 3.43%
- EPS Growth
- FHN 19.36
- QGEN 334.36
- EPS
- FHN 1.64
- QGEN 1.85
- Revenue
- FHN $3,185,000,000.00
- QGEN $2,070,781,000.00
- Revenue This Year
- FHN $12.50
- QGEN $7.37
- Revenue Next Year
- FHN $2.81
- QGEN $5.65
- P/E Ratio
- FHN $12.98
- QGEN $23.78
- Revenue Growth
- FHN 3.75
- QGEN 5.32
- 52 Week Low
- FHN $15.19
- QGEN $37.63
- 52 Week High
- FHN $23.70
- QGEN $51.88
- Technical
- Relative Strength Index (RSI)
- FHN 47.34
- QGEN 29.12
- Support Level
- FHN $20.95
- QGEN $43.26
- Resistance Level
- FHN $21.70
- QGEN $47.39
- Average True Range (ATR)
- FHN 0.46
- QGEN 1.08
- MACD
- FHN 0.10
- QGEN -0.61
- Stochastic Oscillator
- FHN 67.59
- QGEN 7.98
About FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).